clinical trial · NCT06046443
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Hypothalamic ObesityLB54640Placebo
brief summary
The goal of this study is to determine how well LB54640 works and how safe it is in patients with Hypothalamic Obesity (HO). The study will evaluate the effect of LB54640 on safety, weight reduction, hunger, and quality of life in patients 12 years of age and older with HO. Patients will take an oral daily dose of either LB54640 (low, middle, or high dose) or placebo through Week 14. Eligible patients who consent to continue in the study after Week 14 will take an oral daily dose of LB54640 through Week 56.
started
Jul 11, 2024
primary completion
Feb 9, 2026
completion
Feb 9, 2026
last updated
Feb 12, 2026
official title
A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol